At Infinity, we are dedicated to our mission to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. We believe it is essential for patients and caregivers to have access to important information about their diseases and clinical trials.

We’ve provided links to a number of web-based valuable resources for patients. If you are looking for more information about clinical trials, please visit:

• An Introduction to Clinical Trials
• American Cancer Society
• Cancer Care, Inc.
• Gilda’s Club Worldwide
• People Living With Cancer

Infinity is currently evaluating the utility of our lead product candidate,
IPI-504 (retaspimycin hydrochloride) , a novel anti-chaperone agent that potently and selectively inhibits heat shock protein 90 (Hsp90). Infinity has a broad clinical development program underway for IPI-504 targeting several major cancers for which there is a high unmet need. IPI-504 has holds promise in combination as a complement to existing therapies for the treatment of a broad range of tumor types. For information on our ongoing clinical trials, please view our Clinical Trials page or visit www.clinicaltrials.gov. For additional information on these disease settings, please view the links below:

• Gastrointestinal stromal tumors
• Non-small cell lung cancer
• Hormone-refractory prostate cancer